{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:17:49Z","timestamp":1761844669706},"reference-count":47,"publisher":"Spandidos Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.3892\/mmr.2016.5711","type":"journal-article","created":{"date-parts":[[2016,9,5]],"date-time":"2016-09-05T06:19:26Z","timestamp":1473056366000},"page":"3509-3516","source":"Crossref","is-referenced-by-count":6,"title":["Histone deacetylase enzyme silencing using shRNAs enhances radiosensitivity of SW579 thyroid cancer cells"],"prefix":"10.3892","volume":"14","author":[{"given":"Ye","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueming","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongwang","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihai","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2016,9,5]]},"reference":[{"key":"key20180108025647_b1-mmr-14-04-3509","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.1158\/1078-0432.CCR-03-0776","article-title":"Novel histone deacetylase inhibitors in the treatment of thyroid cancer","volume":"11","author":"Mitsiades","year":"2005","journal-title":"Clin Cancer Res"},{"key":"key20180108025647_b2-mmr-14-04-3509","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1038\/sj.onc.1208292","article-title":"High frequency of somatic mitochondrial DNA mutations in human thyroid carcinomas and complex I respiratory defect in thyroid cancer cell lines","volume":"24","author":"Abu-Amero","year":"2005","journal-title":"Oncogene"},{"key":"key20180108025647_b3-mmr-14-04-3509","first-page":"26","article-title":"Inhibitory effects of a novel nutrient mixture on MMP secretion and invasion on human thyroid cancer cell line SW 579","volume":"12","author":"Roomi","year":"2009","journal-title":"JANA"},{"key":"key20180108025647_b4-mmr-14-04-3509","first-page":"292","article-title":"Incidence of thyroid cancer in women in relation to known or suspected risk factors for breast cancer","volume":"47","author":"McTiernan","year":"1987","journal-title":"Cancer Res"},{"key":"key20180108025647_b5-mmr-14-04-3509","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/00001622-200301000-00012","article-title":"Anaplastic thyroid cancer","volume":"15","author":"Pasieka","year":"2003","journal-title":"Curr Opin Oncol"},{"key":"key20180108025647_b6-mmr-14-04-3509","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2165\/00003495-199855060-00007","article-title":"Drug therapy alternatives in the treatment of thyroid cancer","volume":"55","author":"O'Doherty","year":"1998","journal-title":"Drugs"},{"key":"key20180108025647_b7-mmr-14-04-3509","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.ijrobp.2005.05.043","article-title":"Intensity-modulated radiation therapy for the treatment of nonanaplastic thyroid cancer","volume":"63","author":"Rosenbluth","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"key20180108025647_b8-mmr-14-04-3509","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1002\/cncr.22203","article-title":"Clinical outcome of anaplastic thyroid carcinoma treated with radiotherapy of once-and twice-daily fractionation regimens","volume":"107","author":"Wang","year":"2006","journal-title":"Cancer"},{"key":"key20180108025647_b9-mmr-14-04-3509","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/S0360-3016(01)02686-4","article-title":"Papillary thyroid carcinoma: Prognostic factors and the role of radioiodine and external radiotherapy","volume":"52","author":"Chow","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"key20180108025647_b10-mmr-14-04-3509","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1093\/jnci\/djg058","article-title":"Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: A rational advance?","volume":"95","author":"Choy","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"key20180108025647_b11-mmr-14-04-3509","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1158\/1535-7163.MCT-06-0508","article-title":"Combining radiotherapy with AZD2171, a potent inhibitor of vascular endothelial growth factor signaling: pathophysiologic effects and therapeutic benefit","volume":"6","author":"Williams","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"key20180108025647_b12-mmr-14-04-3509","first-page":"117","article-title":"A phase I trial on LBH 589 (panobinostat), a histone deacetylase inhibitor (HDAC) in combination with external radiotherapy for the treatment of prostate cancer, esophageal cancer and head and neck cancer","volume":"3","author":"Coucke","year":"2009","journal-title":"BJMO"},{"key":"key20180108025647_b13-mmr-14-04-3509","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrc1779","article-title":"Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer","volume":"6","author":"Minucci","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"key20180108025647_b14-mmr-14-04-3509","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/onc.2009.306","article-title":"Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation","volume":"29","author":"Borbone","year":"2010","journal-title":"Oncogene"},{"key":"key20180108025647_b15-mmr-14-04-3509","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2217\/fon.11.2","article-title":"Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer","volume":"7","author":"Thurn","year":"2011","journal-title":"Future Oncol"},{"key":"key20180108025647_b16-mmr-14-04-3509","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/sj.cr.7310149","article-title":"HDACs, histone deacetylation and gene transcription: From molecular biology to cancer therapeutics","volume":"17","author":"Gallinari","year":"2007","journal-title":"Cell Res"},{"key":"key20180108025647_b17-mmr-14-04-3509","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s13277-013-1007-5","article-title":"Clinical significance of histone deacetylase (HDAC)-1, HDAC-2, HDAC-4 and HDAC-6 expression in human malignant and benign thyroid lesions","volume":"35","author":"Giaginis","year":"2014","journal-title":"Tumour Biol"},{"key":"key20180108025647_b18-mmr-14-04-3509","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2217\/epi.15.118","article-title":"Histone deacetylase inhibitors as immunomodulators in cancer therapeutics","volume":"8","author":"Shen","year":"2016","journal-title":"Epigenomics"},{"key":"key20180108025647_b19-mmr-14-04-3509","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.cbi.2016.02.018","article-title":"Novel cinnamohydroxamic acid derivatives as HDAC inhibitors with anticancer activity in vitro and in vivo","volume":"249","author":"Wang","year":"2016","journal-title":"Chem Biol Interact"},{"key":"key20180108025647_b20-mmr-14-04-3509","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jss.2006.12.555","article-title":"The HDAC inhibitor trichostatin A inhibits growth of small cell lung cancer cells","volume":"142","author":"Platta","year":"2007","journal-title":"J Surg Res"},{"key":"key20180108025647_b21-mmr-14-04-3509","first-page":"154","article-title":"Can deacetylation promote radioiodide uptake in thyroid cancer?","volume":"9","author":"Clarke","year":"2005","journal-title":"Endocrine Abstracts"},{"key":"key20180108025647_b22-mmr-14-04-3509","doi-asserted-by":"crossref","first-page":"5515","DOI":"10.1073\/pnas.082117599","article-title":"A DNA vector-based RNAi technology to suppress gene expression in mammalian cells","volume":"99","author":"Sui","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180108025647_b23-mmr-14-04-3509","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1093\/nar\/gni065","article-title":"Single copy shRNA configuration for ubiquitous gene knockdown in mice","volume":"33","author":"Seibler","year":"2005","journal-title":"Nucleic Acids Res"},{"key":"key20180108025647_b24-mmr-14-04-3509","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.2147\/OTT.S77709","article-title":"PP4R1 accelerates cell growth and proliferation in HepG2 hepatocellular carcinoma","volume":"8","author":"Wu","year":"2015","journal-title":"Onco Targets Ther"},{"key":"key20180108025647_b25-mmr-14-04-3509","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.ijrobp.2010.06.023","article-title":"A gene expression signature for chemoradiosensitivity of colorectal cancer cells","volume":"78","author":"Spitzner","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"key20180108025647_b26-mmr-14-04-3509","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"key20180108025647_b27-mmr-14-04-3509","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1053\/j.gastro.2011.02.018","article-title":"Pancreatitis, pancreatic and thyroid cancer with glucagon-like peptide-1-based therapies","volume":"141","author":"Elashoff","year":"2011","journal-title":"Gastroenterology"},{"key":"key20180108025647_b28-mmr-14-04-3509","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1200\/JCO.2005.14.167","article-title":"Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer","volume":"23","author":"Kelly","year":"2005","journal-title":"J Clin Oncol"},{"key":"key20180108025647_b29-mmr-14-04-3509","doi-asserted-by":"crossref","first-page":"5570","DOI":"10.1158\/1078-0432.CCR-06-0367","article-title":"Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo","volume":"12","author":"Luong","year":"2006","journal-title":"Clin Cancer Res"},{"key":"key20180108025647_b30-mmr-14-04-3509","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrg816","article-title":"The fundamental role of epigenetic events in cancer","volume":"3","author":"Jones","year":"2002","journal-title":"Nat Rev Genet"},{"key":"key20180108025647_b31-mmr-14-04-3509","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S0959-437X(00)00174-X","article-title":"Functional significance of histone deacetylase diversity","volume":"11","author":"Khochbin","year":"2001","journal-title":"Curr Opin Genet Dev"},{"key":"key20180108025647_b32-mmr-14-04-3509","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.1440-1746.2004.03336.x","article-title":"Downregulation of gelsolin and retinoic acid receptor beta expression in gastric cancer tissues through histone deacetylase 1","volume":"19","author":"Kim","year":"2004","journal-title":"J Gastroenterol Hepatol"},{"key":"key20180108025647_b33-mmr-14-04-3509","first-page":"4287","article-title":"Expression analysis of a subset of coregulators and three nuclear receptors in human colorectal carcinoma","volume":"25","author":"Giannini","year":"2005","journal-title":"Anticancer Res"},{"key":"key20180108025647_b34-mmr-14-04-3509","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10549-004-1668-2","article-title":"Histone deacetylase-1 and-3 protein expression in human breast cancer: A tissue microarray analysis","volume":"90","author":"Krusche","year":"2005","journal-title":"Breast Cancer Res Treat"},{"key":"key20180108025647_b35-mmr-14-04-3509","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.lungcan.2004.03.021","article-title":"Histone deacetylase 1 mRNA expression in lung cancer","volume":"46","author":"Sasaki","year":"2004","journal-title":"Lung Cancer"},{"key":"key20180108025647_b36-mmr-14-04-3509","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1210\/jc.2008-1631","article-title":"Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma","volume":"94","author":"Woyach","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"key20180108025647_b37-mmr-14-04-3509","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1210\/en.2003-1258","article-title":"Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium\/iodide symporter thyroperoxidase and thyroglobulin","volume":"145","author":"Furuya","year":"2004","journal-title":"Endocrinology"},{"key":"key20180108025647_b38-mmr-14-04-3509","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1067\/msy.2002.128690","article-title":"Increasing the effectiveness of radioactive iodine therapy in the treatment of thyroid cancer using Trichostatin A, a histone deacetylase inhibitor","volume":"132","author":"Zarnegar","year":"2002","journal-title":"Surgery"},{"key":"key20180108025647_b39-mmr-14-04-3509","first-page":"465","article-title":"Histone deacetylase inhibitors, but not vincristine, cooperate with radiotherapy to induce cell death in medulloblastoma","volume":"27","author":"Kumar","year":"2007","journal-title":"Anticancer Res"},{"key":"key20180108025647_b40-mmr-14-04-3509","doi-asserted-by":"crossref","DOI":"10.1002\/9781118833322","article-title":"Imaging-guided delivery of RNAi for anticancer treatment","author":"Wang","year":"2016","journal-title":"Adv Drug Deliv Rev"},{"key":"key20180108025647_b41-mmr-14-04-3509","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2165\/00063030-200721010-00003","article-title":"RNAi therapy for HIV infection principles and practicalities","volume":"21","author":"Bennasser","year":"2007","journal-title":"BioDrugs"},{"key":"key20180108025647_b42-mmr-14-04-3509","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1001\/archneurol.2009.180","article-title":"Progress and challenges in RNA interference therapy for Huntington disease","volume":"66","author":"Harper","year":"2009","journal-title":"Arch Neurol"},{"key":"key20180108025647_b43-mmr-14-04-3509","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0070-2153(06)75003-7","article-title":"RNAi therapy for neurodegenerative diseases","volume":"75","author":"Boudreau","year":"2006","journal-title":"Curr Top Dev Biol"},{"key":"key20180108025647_b44-mmr-14-04-3509","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.3892\/or.2014.3353","article-title":"Downregulation of phosphoglycerate kinase 1 by shRNA sensitizes U251 xenografts to radiotherapy","volume":"32","author":"Cheng","year":"2014","journal-title":"Oncol Rep"},{"key":"key20180108025647_b45-mmr-14-04-3509","first-page":"591","article-title":"Silencing of signal transducer and activator of transcription 3 gene expression using RNAi enhances the efficacy of radiotherapy for laryngeal carcinoma in vivo","volume":"44","author":"Wang","year":"2009","journal-title":"Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi"},{"key":"key20180108025647_b46-mmr-14-04-3509","doi-asserted-by":"crossref","first-page":"581732","DOI":"10.1155\/2014\/581732","article-title":"Lentivirus-mediated Nox4 shRNA invasion and angiogenesis and enhances radiosensitivity in human glioblastoma","volume":"2014","author":"Li","year":"2014","journal-title":"Oxid Med Cell Longev"},{"key":"key20180108025647_b47-mmr-14-04-3509","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1093\/carcin\/bgr222","article-title":"Silencing of the Wnt transcription factor TCF4 sensitizes colorectal cancer cells to (chemo-) radiotherapy","volume":"32","author":"Kendziorra","year":"2011","journal-title":"Carcinogenesis"}],"container-title":["Molecular Medicine Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/mmr.2016.5711\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T02:09:26Z","timestamp":1568340566000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/mmr.2016.5711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,5]]},"references-count":47,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2016,9,5]]},"published-print":{"date-parts":[[2016,10]]}},"alternative-id":["10.3892\/mmr.2016.5711"],"URL":"https:\/\/doi.org\/10.3892\/mmr.2016.5711","relation":{},"ISSN":["1791-2997","1791-3004"],"issn-type":[{"value":"1791-2997","type":"print"},{"value":"1791-3004","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,5]]}}}